SCM
ACRS icon

Sterling Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Sterling Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.4K Sell
3,037
-2,251
-43% -$7.59K ﹤0.01% 2302
2025
Q4 		$15.9K Sell
5,288
-692
-12% -$1.75K ﹤0.01% 2354
2025
Q3 		$11.4K Buy
5,980
+3,529
+144% +$6.15K ﹤0.01% 2422
2025
Q2 		$3.48K Buy
+2,451
New +$3.32K ﹤0.01% 2711

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Sterling Capital Management's ACRS Position: Q1 2026 in Review

Sterling Capital Management reduced its Aclaris Therapeutics (ACRS) stake by 43% in Q1 2026, selling an estimated $7.59K and leaving 3,037 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2302.

Sterling Capital Management first reported a position in ACRS in Q2 2025 and has held it in 4 quarters since. The position peaked at $15.9K in Q4 2025. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Sterling Capital Management held 3,037 shares of Aclaris Therapeutics worth $11.4K as of Q1 2026.
  • Sterling Capital Management sold 2,251 Aclaris Therapeutics shares in Q1 2026, an estimated $7.59K.
  • Aclaris Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2302 holding.
  • Sterling Capital Management first reported a position in Aclaris Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Sterling Capital Management's Aclaris Therapeutics position peaked at $15.9K in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.